Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP, GM, Dermatology US

Chairman / CEO

EVP & Chief Financial Officer

EVP, Human Resources

EVP & General Manager US

EVP & Chief Medical Officer

EVP, GMAPPS

EVP, General Manager, Europe

EVP, Head of Tech. Operations

Principal Accounting Officer

EVP & General Counsel

EVP & Chief Scientific Officer

President, R&D

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematolo...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-28	Premium	acquired	Premium	Premium	Premium	-
2024-03-28	Premium	acquired	Premium	Premium	Premium	-
2024-03-28	Premium	acquired	Premium	Premium	Premium	-
2024-03-25	Premium	acquired	Premium	Premium	Premium	EVP, GM, Dermatology US
2024-02-14	Premium	acquired	Premium	Premium	Premium	Chairman / CEO
2024-02-14	Premium	acquired	Premium	Premium	Premium	EVP & Chief Financial Officer
2024-02-14	Premium	acquired	Premium	Premium	Premium	EVP, Human Resources
2024-02-14	Premium	acquired	Premium	Premium	Premium	EVP & General Manager US
2024-02-14	Premium	acquired	Premium	Premium	Premium	EVP & Chief Medical Officer
2024-02-14	Premium	acquired	Premium	Premium	Premium	EVP, GMAPPS
2024-02-12	Premium	sold (taxes)	Premium	Premium	Premium	EVP & Chief Financial Officer
2024-01-22	Premium	sold (taxes)	Premium	Premium	Premium	EVP, General Manager, Europe
2024-01-22	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Head of Tech. Operations
2024-01-19	Premium	sold (taxes)	Premium	Premium	Premium	EVP, General Manager, Europe
2024-01-19	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Head of Tech. Operations
2024-01-18	Premium	acquired	Premium	Premium	Premium	EVP, General Manager, Europe
2024-01-18	Premium	acquired	Premium	Premium	Premium	EVP, Head of Tech. Operations
2024-01-17	Premium	sold (taxes)	Premium	Premium	Premium	EVP & General Manager US
2024-01-17	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Head of Tech. Operations
2024-01-17	Premium	sold (taxes)	Premium	Premium	Premium	EVP, General Manager, Europe
2024-01-17	Premium	sold (taxes)	Premium	Premium	Premium	Principal Accounting Officer
2024-01-16	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Head of Tech. Operations
2024-01-16	Premium	sold (taxes)	Premium	Premium	Premium	EVP, General Manager, Europe
2024-01-03	Premium	sold	Premium	Premium	Premium	EVP & Chief Medical Officer
2024-01-02	Premium	sold	Premium	Premium	Premium	EVP, GMAPPS

INCY - Incyte Corp Stock Price, Fair Value and News

Latest Insider Trading transactions for INCY